The aim of this study is to evaluate whether tumor-derived HGF acts as a potent predictive factor for tumor recurrence and prognosis for patients with gliomas, and whether HGF indeed affects tumor progression by altering the biological behavior of tumor cells and increasing drug resistance. Here, HGF is linked to glioma.